Matches in SemOpenAlex for { <https://semopenalex.org/work/W3184093179> ?p ?o ?g. }
- W3184093179 endingPage "e2117542" @default.
- W3184093179 startingPage "e2117542" @default.
- W3184093179 abstract "Despite guidelines recommending administration of intravenous (IV) magnesium sulfate for refractory pediatric asthma, the number of asthma-related hospitalizations has remained stable, and IV magnesium therapy is independently associated with hospitalization.To examine the association between IV magnesium therapy administered in the emergency department (ED) and subsequent hospitalization among pediatric patients with refractory acute asthma after adjustment for patient-level variables.This post hoc secondary analysis of a double-blind randomized clinical trial of children with acute asthma treated from September 26, 2011, to November 19, 2019, at 7 Canadian tertiary care pediatric EDs was conducted between September and November 2020. In the randomized clinical trial, 816 otherwise healthy children aged 2 to 17 years with Pediatric Respiratory Assessment Measure (PRAM) scores of 5 points or higher after initial therapy with systemic corticosteroids and inhaled albuterol with ipratropium bromide were randomly assigned to 3 nebulized treatments of albuterol plus either magnesium sulfate or 5.5% saline placebo.Intravenous magnesium sulfate therapy (40-75 mg/kg).The association between IV magnesium therapy in the ED and subsequent hospitalization for asthma was assessed using multivariable logistic regression analysis. Analyses were adjusted for year epoch at enrollment, receipt of IV magnesium, PRAM score after initial therapy and at ED disposition, age, sex, duration of respiratory distress, previous intensive care unit admission for asthma, hospitalizations for asthma within the past year, atopy, and receipt of oral corticosteroids within 48 hours before arrival in the ED, nebulized magnesium, and additional albuterol after inhaled magnesium or placebo, with site as a random effect.Among the 816 participants, the median age was 5 years (interquartile range, 3-7 years), 517 (63.4%) were boys, and 364 (44.6%) were hospitalized. A total of 215 children (26.3%) received IV magnesium, and 190 (88.4%) of these children were hospitalized compared with 174 of 601 children (29.0%) who did not receive IV magnesium. Multivariable factors associated with hospitalization were IV magnesium receipt from 2011 to 2016 (odds ratio [OR], 22.67; 95% CI, 6.26-82.06; P < .001) and from 2017 to 2019 (OR, 4.19; 95% CI, 1.99-8.86; P < .001), use of additional albuterol (OR, 5.94; 95% CI, 3.52-10.01; P < .001), and increase in PRAM score at disposition (per 1-U increase: OR, 2.24; 95% CI, 1.89-2.65; P < .001). In children with a disposition PRAM score of 3 or lower, receipt of IV magnesium therapy was associated with hospitalization (OR, 8.52; 95% CI, 2.96-24.41; P < .001).After adjustment for patient-level characteristics, receipt of IV magnesium therapy after initial asthma treatment in the ED was associated with subsequent hospitalization. This association also existed among children with mild asthma at ED disposition. Evidence of a benefit of IV magnesium regarding hospitalization may clarify its use in the treatment of refractory pediatric asthma.ClinicalTrials.gov: NCT01429415." @default.
- W3184093179 created "2021-08-02" @default.
- W3184093179 creator A5001319897 @default.
- W3184093179 creator A5003103543 @default.
- W3184093179 creator A5005366116 @default.
- W3184093179 creator A5011767832 @default.
- W3184093179 creator A5013234447 @default.
- W3184093179 creator A5015115712 @default.
- W3184093179 creator A5016545028 @default.
- W3184093179 creator A5016821733 @default.
- W3184093179 creator A5022291276 @default.
- W3184093179 creator A5023662658 @default.
- W3184093179 creator A5033362442 @default.
- W3184093179 creator A5034980969 @default.
- W3184093179 creator A5040603208 @default.
- W3184093179 creator A5041090623 @default.
- W3184093179 creator A5043801030 @default.
- W3184093179 creator A5052856790 @default.
- W3184093179 creator A5054845268 @default.
- W3184093179 creator A5062701625 @default.
- W3184093179 creator A5064459237 @default.
- W3184093179 creator A5065533338 @default.
- W3184093179 creator A5072749068 @default.
- W3184093179 creator A5079255578 @default.
- W3184093179 creator A5080500730 @default.
- W3184093179 creator A5080740366 @default.
- W3184093179 date "2021-07-19" @default.
- W3184093179 modified "2023-10-03" @default.
- W3184093179 title "Association Between Intravenous Magnesium Therapy in the Emergency Department and Subsequent Hospitalization Among Pediatric Patients With Refractory Acute Asthma" @default.
- W3184093179 cites W154693738 @default.
- W3184093179 cites W1546970761 @default.
- W3184093179 cites W1974246145 @default.
- W3184093179 cites W1998794045 @default.
- W3184093179 cites W2030556594 @default.
- W3184093179 cites W2037668591 @default.
- W3184093179 cites W2054494379 @default.
- W3184093179 cites W2059866170 @default.
- W3184093179 cites W2061729467 @default.
- W3184093179 cites W2064480399 @default.
- W3184093179 cites W2071265265 @default.
- W3184093179 cites W2079452627 @default.
- W3184093179 cites W2098205154 @default.
- W3184093179 cites W2107039911 @default.
- W3184093179 cites W2110826983 @default.
- W3184093179 cites W2113324925 @default.
- W3184093179 cites W2113487248 @default.
- W3184093179 cites W2114724419 @default.
- W3184093179 cites W2130955604 @default.
- W3184093179 cites W2132557753 @default.
- W3184093179 cites W2147339901 @default.
- W3184093179 cites W2153131158 @default.
- W3184093179 cites W2155687796 @default.
- W3184093179 cites W2158067376 @default.
- W3184093179 cites W2398101964 @default.
- W3184093179 cites W2486962012 @default.
- W3184093179 cites W2529480762 @default.
- W3184093179 cites W2559743312 @default.
- W3184093179 cites W2750782721 @default.
- W3184093179 cites W2784917928 @default.
- W3184093179 cites W3010377749 @default.
- W3184093179 cites W3109537815 @default.
- W3184093179 cites W4233083559 @default.
- W3184093179 cites W4246068814 @default.
- W3184093179 cites W4246334934 @default.
- W3184093179 cites W4250535772 @default.
- W3184093179 cites W4320300927 @default.
- W3184093179 doi "https://doi.org/10.1001/jamanetworkopen.2021.17542" @default.
- W3184093179 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8290299" @default.
- W3184093179 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34279646" @default.
- W3184093179 hasPublicationYear "2021" @default.
- W3184093179 type Work @default.
- W3184093179 sameAs 3184093179 @default.
- W3184093179 citedByCount "8" @default.
- W3184093179 countsByYear W31840931792022 @default.
- W3184093179 countsByYear W31840931792023 @default.
- W3184093179 crossrefType "journal-article" @default.
- W3184093179 hasAuthorship W3184093179A5001319897 @default.
- W3184093179 hasAuthorship W3184093179A5003103543 @default.
- W3184093179 hasAuthorship W3184093179A5005366116 @default.
- W3184093179 hasAuthorship W3184093179A5011767832 @default.
- W3184093179 hasAuthorship W3184093179A5013234447 @default.
- W3184093179 hasAuthorship W3184093179A5015115712 @default.
- W3184093179 hasAuthorship W3184093179A5016545028 @default.
- W3184093179 hasAuthorship W3184093179A5016821733 @default.
- W3184093179 hasAuthorship W3184093179A5022291276 @default.
- W3184093179 hasAuthorship W3184093179A5023662658 @default.
- W3184093179 hasAuthorship W3184093179A5033362442 @default.
- W3184093179 hasAuthorship W3184093179A5034980969 @default.
- W3184093179 hasAuthorship W3184093179A5040603208 @default.
- W3184093179 hasAuthorship W3184093179A5041090623 @default.
- W3184093179 hasAuthorship W3184093179A5043801030 @default.
- W3184093179 hasAuthorship W3184093179A5052856790 @default.
- W3184093179 hasAuthorship W3184093179A5054845268 @default.
- W3184093179 hasAuthorship W3184093179A5062701625 @default.
- W3184093179 hasAuthorship W3184093179A5064459237 @default.
- W3184093179 hasAuthorship W3184093179A5065533338 @default.
- W3184093179 hasAuthorship W3184093179A5072749068 @default.
- W3184093179 hasAuthorship W3184093179A5079255578 @default.